A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...